Li Xueling, Wang Jianwei, Hu Linping, Cheng Tao
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China.
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China.
Exp Hematol. 2025 Mar;143:104711. doi: 10.1016/j.exphem.2025.104711. Epub 2025 Jan 7.
Hematopoietic stem cells (HSCs) are central to blood formation and play a pivotal role in hematopoietic and systemic aging. With aging, HSCs undergo significant functional changes, such as an increased stem cell pool, declined homing and reconstitution capacity, and skewed differentiation toward myeloid and megakaryocyte/platelet progenitors. These phenotypic alterations are likely due to the expansion of certain clones, known as clonal hematopoiesis (CH), which leads to disrupted hematopoietic homeostasis, including anemia, impaired immunity, higher risks of hematological malignancies, and even associations with cardiovascular disease, highlighting the broader impact of HSC aging on overall health. HSC aging is driven by a range of mechanisms involving both intrinsic and extrinsic factors, such as DNA damage accumulation, epigenetic remodeling, inflammaging and metabolic regulation. In this review, we summarize the updated understanding of age-related changes in hematopoietic stem and progenitor cells (HSPCs) and the mechanisms underlying the aging process in mammalian models, especially in human study. Additionally, we provide insights into potential therapeutic strategies to counteract aging process and enhance HSC regenerative capacity, which will support therapeutic interventions and promote healthy aging.
造血干细胞(HSCs)是血液形成的核心,在造血和全身衰老过程中起着关键作用。随着年龄的增长,造血干细胞会发生显著的功能变化,如干细胞池增加、归巢和重建能力下降,以及向髓系和巨核细胞/血小板祖细胞的分化偏向。这些表型改变可能是由于某些克隆的扩增,即克隆性造血(CH),这会导致造血稳态破坏,包括贫血、免疫功能受损、血液系统恶性肿瘤风险增加,甚至与心血管疾病有关,凸显了造血干细胞衰老对整体健康的更广泛影响。造血干细胞衰老由一系列涉及内在和外在因素的机制驱动,如DNA损伤积累、表观遗传重塑、炎症衰老和代谢调节。在这篇综述中,我们总结了对造血干细胞和祖细胞(HSPCs)与年龄相关变化的最新认识,以及哺乳动物模型,特别是人类研究中衰老过程的潜在机制。此外,我们还提供了关于对抗衰老过程和增强造血干细胞再生能力的潜在治疗策略的见解,这将支持治疗干预并促进健康衰老。